Core Viewpoint - The recent acceptance of the market application for Mirabegron extended-release tablets by Wuhan Renfu Pharmaceutical has sparked renewed interest in the urology generic drug sector, indicating a competitive landscape with multiple companies vying for market share [1][15]. Group 1: Market Potential - Mirabegron is projected to exceed $1.1 billion in global sales by 2024, establishing itself as a leading treatment for overactive bladder (OAB) [2]. - The drug, developed by Astellas Pharma, is the first selective β3-adrenergic agonist for OAB treatment, addressing a market that has lacked new mechanisms for nearly 30 years [5][6]. Group 2: Competitive Landscape - As of now, 16 domestic pharmaceutical companies have received approval for Mirabegron, indicating a crowded market with significant competition [12]. - Astellas maintains a dominant position in the domestic market, holding a 39.53% market share in hospitals as of the first three quarters of 2025, making it difficult for competitors to disrupt its lead [9]. Group 3: Company Strategies - Wuhan Renfu's application for Mirabegron is part of a broader strategy to enhance its portfolio in the urology specialty and expand its non-anesthesia product line [19]. - The company has over 100 approved products, with 25 being the first in the domestic market, showcasing its commitment to building a strong presence in the generic drug sector [16]. Group 4: Industry Trends - The increasing interest in Mirabegron reflects a shift towards high-potential products that combine new mechanisms, strong demand, and insurance coverage, which are becoming attractive targets for pharmaceutical companies [20]. - The ongoing competition in the generic drug market, particularly for Mirabegron, suggests a potential for value reassessment as companies seek to capitalize on cash flow opportunities in a transforming industry [20].

Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has received the drug registration certificate for Mirabegron Extended-Release Tablets, which enhances the company's product pipeline and addresses overactive bladder symptoms in adults [1][2][3]. Group 1: Drug Information - Drug Name: Mirabegron Extended-Release Tablets - Dosage Form: Tablet - Specification: 50mg - Indication: Symptomatic treatment for adults with overactive bladder (OAB) characterized by urgency, frequency, and/or urge incontinence [1][2]. Group 2: Registration Details - Registration Classification: Chemical Drug Class 4 - Approval Number: National Drug Approval Code H20255960 - Approval Conclusion: The drug meets the requirements for registration as per the Drug Administration Law of the People's Republic of China [2]. Group 3: Impact on the Company - The approval of Mirabegron Extended-Release Tablets enriches the company's product pipeline, although the production and sales of pharmaceutical products may be influenced by national policies and market environment changes, leading to uncertainties [3].

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron sustained-release tablets from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [2] Group 1 - The drug registration certificate number is 2025S03430, which confirms the approval of Mirabegron sustained-release tablets [2]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product [1] Company Summary - Kanghong Pharmaceutical (002773.SZ) has announced the approval of Mirabegron, a selective β3 adrenergic receptor agonist, which acts on bladder tissue to relax bladder smooth muscle [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, marking a significant milestone for the company in the treatment of overactive bladder (OAB) [1] Company Summary - The approved drug, Mirabegron, is a selective β3 adrenergic receptor agonist that relaxes the bladder smooth muscle [1] - The indication for this approval is for the symptomatic treatment of adult patients with overactive bladder, specifically addressing symptoms such as urgency, frequency, and/or urge incontinence [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, indicating regulatory approval for the product [1] Group 1 - The drug Mirabegron is a selective β3 adrenergic receptor agonist [1] - Mirabegron acts on bladder tissue to relax the smooth muscle of the bladder [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Mirabegron Extended-Release Tablets from the National Medical Products Administration, indicating regulatory approval for the product [1] Group 1 - The Drug Registration Certificate number for Mirabegron is 2025S03430 [1] - Mirabegron is a selective β3 adrenergic receptor agonist that relaxes bladder smooth muscle by acting on bladder tissue [1]

Core Viewpoint - Kanghong Pharmaceutical (002773.SZ) has received the Drug Registration Certificate for Mirabegron Extended-Release Tablets from the National Medical Products Administration, indicating regulatory approval for the product [1] Company Summary - Kanghong Pharmaceutical has successfully registered Mirabegron, a selective β3 adrenergic receptor agonist, which acts on bladder tissue to relax bladder smooth muscle [1]

Core Viewpoint - Kanghong Pharmaceutical has received the drug registration certificate for Mirabegron extended-release tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating overactive bladder (OAB) symptoms in adults [1] Group 1 - The product is specifically designed for symptomatic treatment of urinary urgency, frequency, and/or urge incontinence in adult patients with OAB [1]

Core Insights - The company reported a revenue of 41.188 billion yuan for the first half of 2025, representing a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders was approximately 282 million yuan, with a year-on-year increase of 18.56% [1] - The basic earnings per share reached 0.16 yuan, reflecting a growth of 14.29% year-on-year [1] Business Overview - The company is a national wholesale enterprise for narcotic drugs and Class I psychotropic drugs, and it operates in the pharmaceutical and medical device sectors [1] - The main business segments include pharmaceutical commercial operations, covering drug sales, medical devices, traditional Chinese medicine, health products, and supply chain services [1] - The company has expanded its market presence, achieving coverage in all 31 provinces and 164 prefecture-level cities in China [1] Pharmaceutical Wholesale Business - The pharmaceutical wholesale segment generated revenue of 39.052 billion yuan, accounting for over 95% of total revenue, serving more than 8,000 medical institutions [2] - The company is enhancing its "pharmaceutical + internet" strategy, with the online platform "Zhongyao Cloud Business" achieving a transaction volume of approximately 1 billion yuan, a year-on-year increase of 72% [2] Retail Business - The retail segment achieved revenue of 1.947 billion yuan, with brands like "Heping Pharmacy" covering over 850 stores across 22 provinces [2] - The company has opened 616 stores offering outpatient coordination services, improving patient access to medication and health management [2] Product and Service Diversification - The company operates over 280,000 product specifications, with pharmaceutical revenue reaching 33.668 billion yuan and traditional Chinese medicine revenue at 7.210 billion yuan [2] - The company has established standardized planting bases for traditional Chinese medicine and enhanced production capabilities through modern workshops and AI technology [2] Medical Device and Specialty Drugs - The medical device segment generated revenue of 6.884 billion yuan, with 41 SPD projects implemented to improve hospital supply chain management [3] - Revenue from narcotic drugs and Class I psychotropic drugs was 1.736 billion yuan, ensuring stable supply and efficient distribution [3] Innovation and Development - The company is focusing on high-end generic drugs, specialty traditional Chinese medicine, and innovative drug development [3] - Four products, including Mirabegron sustained-release tablets, were approved during the reporting period, with three already in commercial production [3]